• BioMarin Pharmaceutical Inc., of Novato, Calif., reported a GAAP net loss of $53 million, or $0.43 per share for the fourth quarter of 2012, compared to GAAP net loss of $26.7 million, or $0.23 per share for the fourth quarter of 2011 . GAAP net loss for 2012 was $114.3 million, or $0.95 per share, compared to GAAP net loss of $53.8 million, or $0.48 per share, in 2011. Consensus estimates expected a loss of 26 cents per share on $129.4 million in revenues in the quarter. Sales of mucopolysaccharidoses enzyme replacement therapy Naglazyme (galsulfase) totaled $63 million, while sales of phenylketonuria drug Kuvan (sapropterin dihydrochloride) reached $40 million. Sales of Firdapse (amifampridine) for rare autoimmune disease Lambert-Eaton myasthenic syndrome were $3.4 million for the quarter. The firm reported royalties of $23.9 million from partner Genzyme, a unit of Sanofi SA, of Paris, for sales of Aldurazyme (laronidase). As of Dec. 31, 2012, BioMarin had cash, cash equivalents and short- and long-term investments totaling $566.7 million, as compared to $533.2 million on Sept. 30, 2012. The company's shares (NASDAQ:BMRN) closed at $56.10 Friday, up $2.83.

• Exelixis Inc., of South San Francisco, reported a net loss of $52.2million, or ($0.28) per share, for the fourth quarter 2012 compared to an income of $46.3 million, or $0.35 per share, for the comparable period in 2011. Revenues for the quarter were $7.8 million, compared to $93.3 million for the comparable period in 2011. The decrease, the company said, was primarily due to extraordinary one-time revenue events in 2011, including the acceleration of license revenue as a result of the termination of the company's agreement with Bristol Myers-Squibb Company for XL281 in October 2011; the termination in December 2011 of the company's PI3K discovery collaboration with Sanofi, and the transfer in April 2011 of substantially all development activities pertaining to XL147 and XL765 to Sanofi. At the end of the year, the company's cash totaled $634 million compared to $283.7 million at the end of 2011.

• Onyx Pharmaceuticals Inc., of South San Francisco, reported a net loss of $162.9 million, or $2.50 per diluted share, for the full year 2012 and $24 million, or $0.36 per diluted share, for the fourth quarter 2012. Revenue for the full year and fourth quarter of 2012, was $362.2 million and $127.9 million, respectively, as compared to total revenue of $447.2 million and $237.0 million for the comparable periods in 2011. Revenue from their Nexavar collaboration agreement for the full year and fourth quarter of 2012 was $288.4 million and $72.9 million, respectively, as compared to $287.0 million and $76.8 million for the comparable periods in 2011. Kyprolis® (carfilzomib) for Injection generated net sales for the full year of $64 million. On Dec. 31, 2012, cash, cash equivalents and current and noncurrent marketable securities were $492.8 million, compared to $668.4 million at Dec. 31, 2011. The company's shares (NASDAQ:ONXX) closed at $78.31 Friday, up $8.38, or 12 percent.